Literature DB >> 27577931

Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.

Daniela Luvero1, Francesco Plotti1, Alessia Aloisi1, Stella Capriglione2, Roberto Ricciardi1, Andrea Miranda1, Salvatore Lopez1, Giuseppe Scaletta1, Giovanna De Luca1, Pierluigi Benedetti-Panici3, Roberto Angioli1.   

Abstract

We report the long-term follow-up in patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy (NACT) + radical surgery (RS) + adjuvant chemotherapy (ACT) analyzing prognostic factors which may more influence, in a long time, the survival outcome using univariate and multivariate analysis. In this study, we included all patients with diagnosis of locally advanced cervical cancer (IB2-IIB) treated with NACT + RS + ACT from June 2000 and February 2007 as previously described by Angioli et al. (Gynecol Oncol 127(2):290-6, 2012). The primary end-point of the study was overall survival (OS) in patients with node metastases and in those without positive lymph nodes at the end of 10-year follow-up in order to confirm the prognostic role of nodes involvement for a long period. Moreover, we analyzed the impact of other prognostic factors, such as histotype, tumor size, grading and parametrial invasion. Secondary end-point was evaluated in the subgroup of patients with positive nodes the following prognostic factors: number of positive lymph nodes and site of positive lymph nodes. In the subgroup of patients with positive nodes, the OS was 63 %, and in that with negative nodes, the OS was 75 %. On multivariate analysis, the number of nodal metastases, parametrial involvement, grading and the lesion diameter were noted to be significant factors in determining OS. Neither the histotype nor the lymph nodal site is related to survival. Results suggest that CT alone may be an alternative postoperative therapy for patients with cervical cancer.

Entities:  

Keywords:  Adjuvant chemotherapy; Cervical cancer; Locally advanced; Neoadjuvant chemotherapy

Mesh:

Year:  2016        PMID: 27577931     DOI: 10.1007/s12032-016-0830-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

1.  A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery.

Authors:  Roberto Angioli; Francesco Plotti; Alessia Aloisi; Giuseppe Scaletta; Stella Capriglione; Daniela Luvero; Laura Fiore; Corrado Terranova; Roberto Montera; Pierluigi Benedetti Panici
Journal:  Gynecol Oncol       Date:  2015-09-30       Impact factor: 5.482

2.  Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.

Authors:  R Pearcey; M Brundage; P Drouin; J Jeffrey; D Johnston; H Lukka; G MacLean; L Souhami; G Stuart; D Tu
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? A report from the Presidential Panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists.

Authors: 
Journal:  Gynecol Oncol       Date:  1980-08       Impact factor: 5.482

Review 4.  Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature.

Authors:  Roberto Angioli; Daniela Luvero; Alessia Aloisi; Stella Capriglione; Paolo Gennari; Francesca Linciano; Marta Li Destri; Giuseppe Scaletta; Roberto Montera; Francesco Plotti
Journal:  Expert Rev Anticancer Ther       Date:  2014-02-03       Impact factor: 4.512

5.  Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri.

Authors:  J Sardi; C Sananes; A Giaroli; G Maya; G di Paola
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

6.  Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer.

Authors:  B Mossa; S Mossa; R Marziani
Journal:  Eur J Gynaecol Oncol       Date:  2010       Impact factor: 0.196

7.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  Prognostic and treatment factors affecting pelvic control of Stage IB and IIA-B carcinoma of the intact uterine cervix treated with radiation therapy alone.

Authors:  W M Mendenhall; T L Thar; F J Bova; R B Marcus; L S Morgan; R R Million
Journal:  Cancer       Date:  1984-06-15       Impact factor: 6.860

9.  Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.

Authors:  Huijun Chen; Chuan Liang; Lei Zhang; Shuang Huang; Xufeng Wu
Journal:  Gynecol Oncol       Date:  2008-07-07       Impact factor: 5.482

10.  Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

View more
  8 in total

1.  Reply: "Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-years follow-up".

Authors:  D Luvero; F Plotti; R Angioli
Journal:  Med Oncol       Date:  2016-12-24       Impact factor: 3.064

2.  Correspondence on the article: "Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up".

Authors:  Nasir Ali; Ahmed Nadeem Abbasi; Muhammad Atif Mansha
Journal:  Med Oncol       Date:  2016-10-17       Impact factor: 3.064

3.  Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.

Authors:  Nilda E Real; Gisela N Castro; F Darío Cuello-Carrión; Claudia Perinetti; Hanna Röhrich; Niubys Cayado-Gutiérrez; Martin E Guerrero-Gimenez; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2017-06-12       Impact factor: 3.667

4.  PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer.

Authors:  Hongfang Li; Gaogao Sun; Chang Liu; Jing Wang; Rong Jing; Jie Wang; Xiaohuan Zhao; Xiaoyan Xu; Yongxiu Yang
Journal:  Onco Targets Ther       Date:  2017-11-27       Impact factor: 4.147

5.  PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer.

Authors:  Ying Meng; Huyi Liang; Jianguo Hu; Shuaibin Liu; Xiaoming Hao; Micheal Sze Ka Wong; Xiaoyi Li; Lina Hu
Journal:  J Cancer       Date:  2018-07-30       Impact factor: 4.207

6.  Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.

Authors:  Wenjuan Chen; Siyi Xiu; Xingyun Xie; Huiming Guo; Yuanji Xu; Penggang Bai; Xiaoyi Xia
Journal:  Radiat Oncol       Date:  2022-01-10       Impact factor: 3.481

7.  Manifestation of Urinary Tract Injury during Cervical Cancer Surgery Based on CT Urography Secretion Phase Images.

Authors:  Song Lin; Xiaoshan Li; Yan Zhang; Xiaowen Mao; Xingchi Liang; Shigang Cheng; Lingli Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-15       Impact factor: 3.009

8.  Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer.

Authors:  San-Gang Wu; Wen-Wen Zhang; Zhen-Yu He; Jia-Yuan Sun; Yan Wang; Juan Zhou
Journal:  Cancer Manag Res       Date:  2017-12-11       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.